Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc(RARE)股票分析

$15.070

+0.550 (+3.65%)收盤時

Loading chart…
最高
15.080
開盤
14.670
成交量加權均價
14.89
成交量
2.98M
市值
—
最低
14.535
成交金額
44.45M
企業價值/稅息折舊攤銷前利潤(TTM)
-8.21

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company's clinical-stage pipeline consists of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its products include Crysvita (burosumab), Mepsevii (vestronidase alfa), Dojolvi (triheptanoin), and Evkeeza (evinacumab). Crysvita is used for the treatment of X-linked hypophosphatemia, or XLH, in adult and pediatric patients one year of age and older. Mepsevii is used for the treatment of children and adults with mucopolysaccharidosis VII, or MPS VII, also known as Sly syndrome. Dojolvi is used for the treatment of pediatric and adult patients severely affected by long-chain fatty acid oxidation disorders, or LC-FAOD. Evkeeza is used for the treatment of homozygous familial hypercholesterolemia, or HoFH.

AI 分析 of Ultragenyx Pharmaceutical Inc (RARE)

持有

Ultragenyx Pharmaceutical Inc (RARE) is currently trading at $14.54, with a significant upside potential as analysts have raised price targets to as high as $39, suggesting a potential upside of 166% from current levels. However, the stock has a low RSI of 37.885, indicating it may be oversold, and it has experienced a substantial year-to-date decline of 38.39%. The recent sale of a Priority Review Voucher for $210 million is a positive catalyst, providing non-dilutive capital to support its drug development pipeline. The main risk remains its negative net income, which was -92 million in the latest quarter, indicating ongoing financial challenges. Therefore, while there are positive indicators, the stock's volatility and recent performance suggest a cautious approach, making it a hold for now.

分析師評級(18)

上檔空間 +309.09%
買進
10 買進
7 持有
1 賣出
目前: 15.07
最低
35.00
平均
61.65
最高
120.00

Evercore ISI

2026-09-21

目標價

$18

In Line

Barclays

2026-09-21

目標價

$35

增持

Morgan Stanley

2026-09-18

目標價

$20

Equal Weight

Canaccord

2026-09-18

目標價

$39

買進

Cantor Fitzgerald

2026-09-18

目標價

$39

增持

估值指標

Ultragenyx Pharmaceutical Inc(RARE)目前預期本益比為 0.00,5 年平均預期本益比為 -7.25。

預期本益比

嚴重高估
5 年均值 P/E
-7.25
目前P/E
0.00
高估
-5.12
低估
-9.38

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-7.35
目前EV/EBITDA
-8.21
高估
-4.96
低估
-9.75

預期股價營收比

低估
5 年均值 P/S
6.76
目前P/S
1.51
高估
10.13
低估
3.39

Alphio AI 對 RARE 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%RARE

$52.29

情境價格

基

基準

基準 · 50%RARE

$49.73

情境價格

悲

悲觀

悲觀 · 25%RARE

$49.40

情境價格

持有 RARE 的大戶

S

Sofinnova Investments, Inc.

+ 持有RARE

+8.73%

3個月報酬率

B

Bellevue Asset Management AG

+ 持有RARE

-0.81%

3個月報酬率

B

Bluebox Asset Management Uk Ltd.

+ 持有RARE

-1.54%

3個月報酬率

P

Pale Fire Capital SE

+ 持有RARE

-1.86%

3個月報酬率

B

BIT Capital GmbH

+ 持有RARE

-4.75%

3個月報酬率

R

RTW Investments, LP

+ 持有RARE

-10.67%

3個月報酬率

RARE 常見問題 —— 由 Alphio AI 解答

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company's clinical-stage pipeline consists of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its products include Crysvita (burosumab), Mepsevii (vestronidase alfa), Dojolvi (triheptanoin), and Evkeeza (evinacumab). Crysvita is used for the treatment of X-linked hypophosphatemia, or XLH, in adult and pediatric patients one year of age and older. Mepsevii is used for the treatment of children and adults with mucopolysaccharidosis VII, or MPS VII, also known as Sly syndrome. Dojolvi is used for the treatment of pediatric and adult patients severely affected by long-chain fatty acid oxidation disorders, or LC-FAOD. Evkeeza is used for the treatment of homozygous familial hypercholesterolemia, or HoFH. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Ultragenyx Pharmaceutical Inc (RARE) is currently trading at $14.54, with a significant upside potential as analysts have raised price targets to as high as $39, suggesting a potential upside of 166% from current levels. However, the stock has a low RSI of 37.885, indicating it may be oversold, and it has experienced a substantial year-to-date decline of 38.39%. The recent sale of a Priority Review Voucher for $210 million is a positive catalyst, providing non-dilutive capital to support its drug development pipeline. The main risk remains its negative net income, which was -92 million in the latest quarter, indicating ongoing financial challenges. Therefore, while there are positive indicators, the stock's volatility and recent performance suggest a cautious approach, making it a hold for now.

18 analysts cover RARE: 10 rate it Buy, 7 Hold and 1 Sell. The average price target is 61.65.

humblemarten2026/9/28

Most traders are looking for the next coin that will pump. I'm looking for something else. WHO IS BUYING THE DIPS? Because a green candle tells you what already happened. The reaction after the candle tells you whether the move has real strength. Look at the market right now: BTC is still the liquidity anchor. ETH is trying to regain momentum. SOL and XRP are fighting for attention. ZEC is showing extreme volatility. And names like QNT and HBAR have already shown what happens when liquidity suddenly rotates into a narrative. But here's where traders get trapped: A coin pumps 20–30%. Everyone notices. Everyone starts talking about it. Then late buyers enter. And the original buyers start taking profit. That is how a bullish chart can turn into a brutal trap. ━━━━━━━━━━━━━━ 🧠 HERE'S THE TEST I USE I don't care how big the breakout candle is. I want to see what happens NEXT. Breakout → pullback → buyers defend → higher low → continuation. That is a much healthier structure. But: Breakout → instant FOMO → volume disappears → support breaks. That's distribution risk. Same green candle. Completely different market structure. ━━━━━━━━━━━━━━ ₿ AND THIS IS WHY BTC MATTERS If BTC holds its major support while an altcoin is building higher lows, I'm interested. If BTC starts losing structure while an altcoin is already massively extended, I'm much more careful. Because when liquidity leaves the market: BTC usually reacts first. High-beta alts can react MUCH harder. That's where leverage becomes dangerous. ━━━━━━━━━━━━━━ 🔥 MY CURRENT WATCHLIST BTC — market direction ETH — relative strength SOL — high-beta momentum XRP — large-cap rotation ZEC — extreme volatility QNT / HBAR — momentum after major expansion But I'm NOT chasing the biggest green candle. I'm waiting for the market to prove that buyers are willing to defend the move. ━━━━━━━━━━━━━━ THE HARDEST SKILL IN TRADING ISN'T FINDING A COIN. IT'S KNOWING WHEN NOT TO CHASE IT. You don't need to catch every pump. You need to survive long enough to catch the setups that actually matter. ━━━━━━━━━━━━━━ 👇 ONE QUESTION: If you could trade ONLY ONE for the next 7 days: BTC ETH SOL XRP ZEC QNT HBAR Which one are you choosing — and WHY? Don't just drop the ticker. Give me your reason. I'll reply with the key level I'd be watching. $QNT $RARE $BTC

展開
humblemarten2026/9/27

⚡ FUTURES MARKET ROTATION: TWO SIDES OF THE SAME MOVE QNT • SOON • ARX • BTW • GRASS | PHA • RARE • BR • Q • KMNO September 27, 2026 The latest Futures screen shows a sharp split in market momentum: some contracts are attracting aggressive upside participation, while others are experiencing rapid downside pressure. 🟢 FUTURES GAINERS QNTUSDT — +54.98% SOONUSDT — +35.30% ARXUSDT — +25.83% BTWUSDT — +20.83% GRASSUSDT — +19.69% QNT is clearly leading this snapshot, while SOON and ARX are also showing strong short-term expansion. When several contracts move together, it can indicate concentrated momentum rather than a broad market-wide trend. But strong percentage moves also deserve context. Fast expansion can bring higher volatility, wider intraday swings and rapid reversals, especially in leveraged markets. 🔴 FUTURES LOSERS PHAUSDT — -18.26% RAREUSDT — -15.24% BRUSDT — -13.58% QUSDT — -13.24% KMNOUSDT — -12.86% The downside list tells a different story. PHA is showing the largest decline in this snapshot, followed by RARE and BR. Q and KMNO are also under noticeable short-term pressure. 🧠 WHAT THIS ACTUALLY TELLS US The interesting part isn't simply which token is green or red. It's the speed of the rotation. When futures contracts experience large moves on both sides at the same time, traders should pay attention to: • Momentum persistence vs. sudden reversal • Volume confirmation • Open interest changes • Funding conditions • Liquidation activity • Whether spot markets confirm the futures move A large percentage change alone doesn't explain the underlying market structure. 📌 Key takeaway: This is a snapshot of short-term futures momentum, not a confirmation of a longer-term trend. The strongest-looking move can also become the most volatile one. ⚠️ Risk Disclaimer: This post is for educational and informational purposes only. Futures and leverage involve substantial risk, and rapid price movements can result in significant losses. Always conduct your own research and manage risk carefully. $BTC $RARE $SOONNEW

展開
wolf_gust2026/9/27

$RARE 🔻 RARE — Bearish Setup Current Price: 0.019 Entry: 0.0190–0.0192 TP1: 0.0183 TP2: 0.0176 TP3: 0.0168 SL: 0.0198 Confirmation: A clean break below 0.0188 would strengthen the downside setup.

展開
alpha_baker2026/9/27

$QNT $SOON $RARE 📌 FOMC isn’t just about the rate decision. Traders also watch Fed guidance, market expectations, and BTC’s reaction. Sometimes the biggest move comes from the gap between what was expected and what actually happened. 📊

展開
註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易